一个双盲,安慰剂对照试验的甲基普雷迪尼索隆脉冲疗法在活跃的类风湿性疾病
Lancet (London, England)
|July 31, 1982
概括
甲基prednisolone脉冲疗法 (MPPT) 有效治疗活跃的类风湿性疾病,显示持续的临床益处. 这次双盲试验证实了MPPT.
科学领域:
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 不受控制的试验表明,甲基prednisolone脉冲疗法 (MPPT) 对类风湿性疾病是安全的.
- 需要严格确认MPPT在活跃类风湿性疾病中的疗效和安全性.
研究的目的:
- 通过双盲试验确认MPPT在活跃类风湿性疾病中的安全性和有效性.
- 评估MPPT的临床,血液学和生物化学效应.
主要方法:
- 这是一项双盲随机试验,涉及20名患有活跃类风湿性疾病的患者.
- 患者接受了1g甲基prednisolone输液或安慰剂.
- 随着时间的推移,评估了临床变量,安慰剂患者后来接受了甲基prednisolone.
主要成果:
- 甲基普雷尼索隆显著改善了所有测量的临床变量至少6周.
- 在一些变量中,安慰剂只能提供暂时的改善.
- 在安慰剂患者中随后的甲基普雷迪尼索隆治疗也产生了显著的临床益处.
- 在一些血液学和生化标志物中观察到改善.
结论:
- 甲基prednisolone脉冲疗法是一种安全有效的治疗活性类风湿性疾病.
- MPPT证明了持续的临床益处和对某些生物标志物的积极影响.
- 这些发现支持使用MPPT来管理活跃的类风湿性疾病.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
